Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat

被引:16
作者
Wright, AWE [1 ]
Dickinson, RG [1 ]
机构
[1] Univ Queensland, Royal Brisbane Hosp, Ctr Studies Drug Disposit, Brisbane, Qld 4029, Australia
关键词
D O I
10.1124/jpet.103.064220
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Valproic acid (VPA) is a major therapeutic agent in the treatment of epilepsy and other neurological disorders. It is metabolized in humans and rats primarily along two pathways: direct glucuronidation to yield the acyl glucuronide (VPA-G) and beta-oxidation. We have shown much earlier in the Sprague-Dawley rat that i.v. administration of sodium valproate (NaVPA) caused a marked choleresis ( mean of 3.3 times basal bile flow after doses of 150 mg/kg), ascribed to the passive osmotic flow of bile water following excretion of VPA-G across the canalicular membrane. Active biliary pumping of anionic drug conjugates across the canalicular membrane is now believed to be attributable to transporter proteins, in particular Mrp2, which is deficient in the TR- ( a mutant Wistar) rat. In the present study, normal Wistar and Mrp2-deficient TR- rats were dosed i.v. with NaVPA at 150 mg/kg. In the Wistar rats, there was a peak choleretic effect of about 3.2 times basal bile flow, occurring at about 30 to 45 min postdose ( as seen previously with Sprague-Dawley rats). In TR- rats given the same i.v. dose, there was no evidence of postdose choleresis. The choleresis was correlated with the excretion of VPA-G into bile. In Wistar rats, 62.8 +/- 7.7% of the NaVPA dose was excreted in bile as VPA-G, whereas in TR- rats, only 2.0 +/- 0.6% of the same dose was excreted as VPA-G in bile ( with partial compensatory excretion of VPA-G in urine). This study underlines the functional ( bile flow) consequences of biliary transport of xenobiotic conjugated metabolites.
引用
收藏
页码:584 / 588
页数:5
相关论文
共 18 条
[1]   Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy [J].
Cao, JS ;
Stieger, B ;
Meier, PJ ;
Vore, M .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2002, 283 (03) :G757-G766
[2]   HEPATIC, INTESTINAL AND RENAL TRANSPORT OF 1-NAPHTHOL-BETA-D-GLUCURONIDE IN MUTANT RATS WITH HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA [J].
DEVRIES, MH ;
REDEGELD, FAM ;
KOSTER, AS ;
NOORDHOEK, J ;
DEHAAN, JG ;
ELFERINK, RPJO ;
JANSEN, PLM .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1989, 340 (05) :588-592
[3]  
DICKINSON RG, 1979, J PHARMACOL EXP THER, V211, P583
[4]   URINARY-EXCRETION OF VALPROATE AND SOME METABOLITES IN CHRONICALLY TREATED PATIENTS [J].
DICKINSON, RG ;
HOOPER, WD ;
DUNSTAN, PR ;
EADIE, MJ .
THERAPEUTIC DRUG MONITORING, 1989, 11 (02) :127-133
[5]  
DICKINSON RG, 1980, J PHARMACOL EXP THER, V213, P38
[6]  
DICKINSON RG, 1982, ARZNEIMITTELFORSCH, V32-1, P241
[7]   Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver [J].
Donner, MG ;
Keppler, D .
HEPATOLOGY, 2001, 34 (02) :351-359
[8]   HEPATOBILIARY TRANSPORT OF GLUTATHIONE AND GLUTATHIONE CONJUGATE IN RATS WITH HEREDITARY HYPERBILIRUBINEMIA [J].
ELFERINK, RPJ ;
OTTENHOFF, R ;
LIEFTING, W ;
DEHAAN, J ;
JANSEN, PLM .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (02) :476-483
[9]   QUANTITATIVE-DETERMINATION OF VALPROIC ACID AND 14 METABOLITES IN SERUM AND URINE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
FISHER, E ;
WITTFOHT, W ;
NAU, H .
BIOMEDICAL CHROMATOGRAPHY, 1992, 6 (01) :24-29
[10]   Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan [J].
Fouassier, L ;
Kinnman, N ;
Lefèvre, G ;
Lasnier, E ;
Rey, C ;
Poupon, R ;
Elferink, RPJO ;
Housset, C .
JOURNAL OF HEPATOLOGY, 2002, 37 (02) :184-191